Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Vinva Investment Management Ltd

Vinva Investment Management Ltd decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 59.1% during the 4th quarter, Holdings Channel reports. The firm owned 13,264 shares of the medical equipment provider’s stock after selling 19,145 shares during the quarter. Vinva Investment Management Ltd’s holdings in Hologic were worth $959,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HOLX. Swedbank AB grew its holdings in Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Hologic by 22.2% in the third quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock valued at $469,000 after purchasing an additional 1,048 shares during the last quarter. OneDigital Investment Advisors LLC lifted its position in shares of Hologic by 5.4% in the third quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock valued at $576,000 after acquiring an additional 360 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Hologic by 8.8% in the third quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 291 shares in the last quarter. Finally, Pathstone Holdings LLC lifted its position in shares of Hologic by 7.7% in the third quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider’s stock valued at $2,422,000 after acquiring an additional 2,121 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on HOLX. Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Stephens restated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Raymond James restated an “outperform” rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Royal Bank of Canada reduced their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Shares of NASDAQ:HOLX opened at $61.01 on Friday. The firm has a market capitalization of $13.69 billion, a PE ratio of 19.25, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business has a 50-day moving average of $66.26 and a two-hundred day moving average of $74.19. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.